Denali Therapeutics earnings were -$422.8M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest DNLI earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$114.8M, up 7.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, DNLI reported annual earnings of -$422.8M, with 191.1% growth. The next DNLI earnings date is May 5, 2025.
Denali Therapeutics Earnings Reports & History FAQ
What were Denali Therapeutics's earnings last quarter?
On DNLI's earnings call on Invalid Date, Denali Therapeutics (NASDAQ: DNLI) reported Q4 2024 earnings per share (EPS) of -$0.68, up 21.84% year over year. Total DNLI earnings for the quarter were -$114.75 million. In the same quarter last year, Denali Therapeutics's earnings per share (EPS) was -$0.87.
The next DNLI earnings date is Invalid Date. Add DNLI to your watchlist to be reminded of Denali Therapeutics's next earnings date.
What was DNLI's earnings growth in the past year?
As of Denali Therapeutics's earnings date in Invalid Date, Denali Therapeutics's earnings has grown year over year. DNLI earnings in the past year totalled -$422.77 million.
Is Denali Therapeutics profitable or losing money?
As of the last Denali Therapeutics earnings report, Denali Therapeutics is currently losing money. Denali Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$422.77 million, a 191.12% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.